The U.S. FDA announced that patients taking care of with Cubicin, an intravenous antibiotic, sprint an augmented threat of rising eosinophilic pneumonia, a uncommon and potentially life-threatening situation.

Cubicin is the trade name for the generic medicine daptomycin. The medicine was first permitted in 2003 for taking care of severe skin infections and in 2006 to treat bloodstream infections and it was marketed by Massachusetts-based Cubist Pharmaceuticals.

The medicine label was customized to contain warning for an augmented threat of pulmonary eosinophilia, a situation marked by an enlarged deliberation of eosinophils in the blood in 2007.

It has recognized seven established cases of eosinophilic pneumonia involving 2004 and 2010 also 36 additional probable cases, according to the medical literature and adverse event reports of the FDA.

In the entire seven long-established cases, the adults older than 60 years of age were being treated with Cubicin for non-FDA standard conditions like osteomyelitis and prosthetic hip infection.

Despite the fact that the indications for all patients come into view in two weeks of the instigation of Cubicin therapy, they determined upon not continuation of drug. The symptoms resurface in two patients when the treatment was resumed.

In the extra 36 probable cases of eosinophilic pneumonia connected with Cubicin treatment, the six agency criterions for a possible case of association were not gathering totally. Though, they give a considerable sustain for connecting the antibiotic and the disorder, FDA declared.

“Support on these evaluations, FDA indomitable that eosinophilic pneumonia can be linked with Cubicin use and demanded that the manufacturer of Cubicin comprise this information in the Warnings and Precautions and Adverse Reactions, Post-Marketing Experience sections of the drug label,” the statement issued by the agency in a Drug Safety Communication read.

The group has called for a tagging modification for the drug. It has also suggested that physicians must strongly check patients being treated with Cubicin for signs of eosinophilic pneumonia.

Eosinophilic pneumonia is an uncommon and potentially severe type of pneumonia wherein a definite form of white blood cells called eosinophils fill up the lungs.

The disorderly buildup of cells disturbs alveoli, the usual air spaces where oxygen is removed from the breathed in air. A holdup in analyzes and take notes treatment for the situation can effect in progressive respiratory breakdown and yet death.

Illustrated by indications similar to cough, fever, difficulty breathing, and sweating at night, the illness can bother people in some age group. The existence of EP is typically chosen by a mixture of feature sign, physical examination, blood screening, and X-ray examination

Tags | Antibiotic Cubicin, daptomycin, Eosinophilic Pneumonia, FDA, osteomyelitis, pulmonary eosinophilia